Old West Investment Management LLC Acquires Shares of 667,103 Bruker Corporation $BRKR

Old West Investment Management LLC purchased a new stake in shares of Bruker Corporation (NASDAQ:BRKR) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 667,103 shares of the medical research company’s stock, valued at approximately $40,146,000. Bruker comprises about 4.3% of Old West Investment Management LLC’s investment portfolio, making the stock its largest position. Old West Investment Management LLC owned about 0.44% of Bruker at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in BRKR. Global Retirement Partners LLC acquired a new position in Bruker during the 2nd quarter worth about $38,000. Bank of New York Mellon Corp acquired a new stake in Bruker in the 2nd quarter valued at about $44,839,000. GSA Capital Partners LLP bought a new position in shares of Bruker in the second quarter worth about $695,000. Walleye Trading LLC acquired a new position in shares of Bruker during the second quarter worth approximately $2,702,000. Finally, Handelsbanken Fonder AB lifted its position in shares of Bruker by 49.6% during the second quarter. Handelsbanken Fonder AB now owns 54,805 shares of the medical research company’s stock worth $3,298,000 after purchasing an additional 18,165 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

BRKR has been the subject of a number of research reports. TD Cowen reissued a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Guggenheim upped their price objective on Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Stifel Nicolaus set a $50.00 target price on Bruker in a research note on Wednesday, August 5th. Citigroup dropped their target price on Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research report on Wednesday, August 5th. Finally, Wall Street Zen raised Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $56.64.

Bruker Stock Performance

Shares of BRKR stock opened at $57.70 on Monday. The stock has a market cap of $8.79 billion, a PE ratio of -82.43, a price-to-earnings-growth ratio of 1.76 and a beta of 1.28. The stock has a 50-day moving average of $58.36 and a 200-day moving average of $47.04. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. Bruker Corporation has a one year low of $28.53 and a one year high of $65.30.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The firm had revenue of $838.50 million during the quarter, compared to analysts’ expectations of $853.57 million. During the same quarter in the previous year, the company earned $0.32 earnings per share. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts expect that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.